Drug
Telaprevir clinical trials
Also written VX-950, Incivek, MP-424 and INCIVO.
- studies test it
- 67
- open now
- 0
- in phase 3
- 23
- first study started
- 2005
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
67 studies that test it; most in 2012 (21)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 10 |
| 2009 | 5 |
| 2010 | 2 |
| 2011 | 8 |
| 2012 | 21 |
| 2013 | 10 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 17
- Phase 3
- 23
- Phase 4
- 5
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 54 · Other 13
Vertex Pharmaceuticals Incorporated (18) · Tanabe Pharma Corporation (10) · Tibotec BVBA (7) · Janssen-Cilag International NV (4) · Janssen Infectious Diseases BVBA (4) · ViiV Healthcare (2) · Bristol-Myers Squibb (2) · Santaris Pharma A/S (2)
Often tested with
Tested in the same studies.
Ribavirin (30) · Peginterferon alfa-2a (15) · Peginterferon alfa-2b (6) · Boceprevir (3) · Lomibuvir (3) · Daclatasvir (2) · Miravirsen (2) · Interferons (2)
Studies
Open first, then newest update. How each study uses telaprevir is read from its arms, and is right about nine times in ten.
Testing it · 67
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT01332955Written as Telaprevir
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00781274Written as MP-424
- Safety and PK Study of MP-424 to Treat Chronic Hepatitis CCompletedPhase 1Tanabe Pharma CorporationNCT00591214Written as MP-424 (Telaprevir)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01466192Written as MP-424 (generic name:Telaprevir)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT01753557Written as MP-424
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedPhase 1Tanabe Pharma CorporationNCT00630058Written as MP-424(H), PEG-IFN-a-2b, RBV
- Safety and Efficacy of MP-424 to Treat Chronic Hepatitis CCompletedPhase 2Tanabe Pharma CorporationNCT00621296Written as MP-424 (Telaprevir)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT00780416Written as MP-424
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00780910Written as MP-424
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01468584Written as MP-424 (generic name:Telaprevir)
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedPhase 3Tanabe Pharma CorporationNCT01753570Written as MP-424
- Telaprevir in Genotype 3 HCVCompletedPhase 4Queen Mary University of LondonNCT02087111Written as Telaprevir
- A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT00758043Written as telaprevir
- Interaction Between Paroxetine and TelaprevirTerminatedPhase 2Radboud University Medical CenterNCT01841502Written as telaprevir
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)TerminatedPhase 3M.D. Anderson Cancer CenterNCT01821963Written as Telaprevir
- Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1CompletedPhase 2University of FloridaNCT01994486Written as Telaprevir and Sofosbuvir
- Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01657552Written as Telaprevir
- Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC PolymorphismWithdrawnPhase 4University of VermontNCT01415141Written as telaprevir
- Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)CompletedPhase 3St Stephens Aids TrustNCT02006745Written as Telaprevir
- A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).CompletedPhase 1ViiV HealthcareNCT01563328Written as TVR
See all 67 studies that test telaprevir →
Given in every arm · 8 — telaprevir is usual care beside what is tested
- Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis CTerminatedPhase 2MassBiologicsNCT01532908Written as Telaprevir (Part 1)
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedPhase 2Vertex Pharmaceuticals IncorporatedNCT01080222Written as telaprevir
- Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedPhase 3Bristol-Myers SquibbNCT01598090Written as Telaprevir
- Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501CompletedPhase 2Eisai Inc.NCT01355289Written as Telaprevir
- A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01482390Written as Telaprevir
- An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C ParticipantsCompletedPhase 2Tibotec BVBANCT00528528Written as Telaprevir
- Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1WithdrawnPhase 2/3Timothy Morgan, MDNCT01890772Written as Telaprevir
- A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy AdultsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01038167Written as telaprevir
As the comparator · 4 — what is tested is compared with telaprevir
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as Telaprevir
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced AdultsCompletedPhase 3AbbVieNCT01854528Written as Telaprevir
- Dose Ranging of GSK2336805 in Combination TherapyCompletedPhase 2GlaxoSmithKlineNCT01648140Written as Telaprevir
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCompletedPhase 3Bristol-Myers SquibbNCT01718145Written as Telaprevir
Codes
What other systems call telaprevir · ClinicalTrials.gg INT004648
- MeSH (NLM) C486464telaprevirConfirmed NLM, Wikidata
- UNII (FDA) 655M5O3W0UTELAPREVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1102261Confirmed FDA, Wikidata
- Wikidata Q408557telaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81603TelaprevirOne source FDA
- DrugBank DB05521One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C486464 | telaprevir | Confirmed NLM, Wikidata |
| UNII (FDA) | 655M5O3W0U | TELAPREVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1102261 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408557 | telaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81603 | Telaprevir | One source FDA |
| DrugBank | DB05521 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.